United States

Zoetis Launches Clavamox® Chewable for Dogs and Cats

Trusted antibiotic is now available in a highly palatable,1 easy-to-administer chewable tablet

PARSIPPANY, N.J. — Aug. 14, 2017 — Zoetis today announced the commercial launch of Clavamox® Chewable (amoxicillin and clavulanate potassium tablets), which is effective in treating skin infections in dogs and cats, periodontal infections in dogs and urinary tract infections in cats. This product was approved by the U.S. Food and Drug Administration on May 24, 2017. As a highly palatable,1 easy-to-administer formulation, Clavamox Chewable features the same broad-spectrum efficacy, dosing, and strengths as the original film-coated Clavamox Tablet that has been used by veterinarians for decades. Clavamox Chewable is now available to all veterinarians in the United States.

“Clavamox Chewable is a prime example of how we focus our innovation at Zoetis on addressing the challenges of our veterinary customers and improving the lives of the animals in their care,” said J. Michael McFarland, DVM, DAVBP, Executive Director, Companion Animal Marketing. “This innovation was made possible by our customers’ loyal support of the Clavamox brand over more than 30 years.”

This new chewable formulation combines the reliability and effectiveness of Clavamox with the same pork-liver-flavored chewable base used in Rimadyl® (carprofen) Chewable. The palatability of Clavamox Chewable was established in a clinical trial that studied client-owned dogs at VCA veterinary hospitals across the U.S. and was conducted to a protocol approved by FDA’s Center for Veterinary Medicine. A total of 1,567 doses were administered to 112 dogs, resulting in an 83 percent overall voluntary acceptance rate for Clavamox Chewable when offered from an empty bowl or owner’s hand.*,1 This clinical trial is an example of a successful collaboration between Zoetis, the world’s largest animal health company, and a global veterinary hospital corporation, VCA.

Clavamox Chewable is available in four strengths (62.5 mg, 125 mg, 250 mg and 375 mg) and is packaged in boxes of 100 tablets. Veterinarians can continue to purchase Clavamox Drops and original film-coated Clavamox Tablet formulations.

For more information about Clavamox Chewable and full Prescribing Information, visit clavamoxchewable.com.

IMPORTANT SAFETY INFORMATION:
People with known hypersensitivity to penicillin or cephalosporins should avoid exposure to Clavamox Chewable. Do not use in animals with a history of allergic reactions to penicillins or cephalosporins.

About Zoetis
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2016, the company generated annual revenue of $4.9 billion with approximately 9,000 employees. For more information, visit www.zoetis.com.

For Further information contact:
Colleen White       
Zoetis        
973-822-7203      
colleen.white@zoetis.com

Lindsey Goodman
Archer Malmo
706-201-6721
lgoodman@archermalmo.com

References:
*One hundred twelve (112) dogs with 1567 total tablet administrations successfully completed the study and were included in the data summary. Of the 1567 doses administered, CLAVAMOX CHEWABLE tablets were fully consumed within five minutes 82.51% of the time. Tablets were fully consumed within two minutes 81.17% of the time. The percent acceptance was consistent over 14 doses (seven days). For the first dose given, 93/112 dogs (83.04%) consumed the entire dose within two minutes. For the last (14th) dose, 89/111 dogs (80.18%) consumed the entire dose within two minutes, indicating that tablet acceptability continued over time without development of aversion to the tablet(s).

1Data on file. CLAVAMOX CHEWABLE Tablets Palatability Study in Client-Owned Dogs. Study No. A163C-US-13-170, Zoetis Inc.